Novo Nordisk invests more than 16 billion Danish kroner in expansion of production facilities in Chartres, France
November 23, 2023 11:02 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 23 November 2023 – Novo Nordisk today announced the investment of more than 16 billion Danish kroner (2.1 billion euros) starting in 20231 to expand the existing production site in...
Novo Nordisk A/S - share repurchase programme
November 20, 2023 10:03 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 20 November 2023 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
November 14, 2023 06:07 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 14 November 2023 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated...
Novo Nordisk A/S - share repurchase programme
November 13, 2023 14:30 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 13 November 2023 – On 6 November 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and...
Trading in Novo Nordisk shares by board members, executives and associated persons
November 13, 2023 07:04 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 13 November 2023 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated...
Novo Nordisk A/S: Semaglutide 2.4 mg (Wegovy®) cardiovascular outcomes data presented at American Heart Association Scientific Sessions and simultaneously published in New England Journal of Medicine
November 11, 2023 08:31 ET
|
Novo Nordisk A/S
Semaglutide 2.4 mg delivered a statistically significant 20% risk reduction in major adverse cardiovascular events (MACE) with risk reductions demonstrated consistently across age, gender, ethnicity...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
November 10, 2023 06:39 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 10 November 2023 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated...
Novo Nordisk invests more than 42 billion Danish kroner in expansion of manufacturing facilities in Kalundborg, Denmark
November 10, 2023 01:30 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 10 November 2023 – Novo Nordisk today announced plans to invest more than 42 billion Danish kroner starting in 20231 to expand existing manufacturing facilities in Kalundborg,...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
November 07, 2023 10:19 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 7 November 2023 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated...
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
November 06, 2023 16:14 ET
|
Novo Nordisk A/S
Bagsværd, Denmark, 6 November 2023 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated...